Journal: Therapeutic Advances in Vaccines and Immunotherapy
Article Title: Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus
doi: 10.1177/25151355221144845
Figure Lengend Snippet: New drugs mechanism of action against SARS-CoV-2 or COVID-19. Promising results of new drugs against new coronavirus or the disease. PF-07304814 acts blocking the 3CL protease from SARS-CoV-2 avoiding the cell infection. RBT-9 is an antiviral drug blocking virus replication. TD-0903 blocks the JAK-STAT signaling mediated by the cytokine storm avoiding the damages caused by the exacerbation of pro-inflammatory response in the lung. M5049 is an antagonist of TLR7/8 that can recognize the viral RNA and stimulates the innate immune response with higher expression of pro-inflammatory cytokine genes, as IL-6. The use of M5049 helps the pro-inflammatory cytokine storm avoiding the inflammatory damage caused by the infection. BLD-2660 blocks the IL-6 action during the cytokine storm caused by the new coronavirus.
Article Snippet: TD-0903 , Immunomodulator (JAK inhibition) developed for the treatment of acute lung injury due to COVID-19 , TD-0903 for ALI Associated With COVID-19 , Theravance Biopharma , Phase II , NCT04402866 , Republic of Moldova, Romania, Ukraine, and United Kingdom.
Techniques: Blocking Assay, Infection, Expressing